论文部分内容阅读
目的：探讨高危型人乳头状瘤病毒（hr-HPV DNA）检测对意义不明确的宫颈非典型鳞状细胞（ASC-US）患者临床处理的指导意义。方法经宫颈液基薄层细胞学检查（TCT）诊断为ASC-US的197例患者分别行hr-HPV DNA检测及阴道镜下活检，分析hr-HPV感染阳性组与阴性组中鳞状上皮病变有无差异，hr-HPV DNA检测对鳞状上皮病变的预测价值。结果 hr-HPV DNA 检测对ASC-US中鳞状上皮病变发现的敏感度，特异度，阳性预测值，阴性预测值分别为86.4%，75.2%，50.0%，95.1%。阳性组与阴性组中鳞状上皮病变的发生率为50.0%和5.0%，差异有统计学意义（P<0.05）。结论 hr-HPV DNA检测对ASC-US病例的进一步处理有指导分流作用，hr-HPV DNA阳性组可进一步行阴道镜下活检， hr-HPV DNA阴性组可于一段时间后复查宫颈细胞学。“,”Objective To evaluate the use of the high-risk human papillomavirus (hr-HPV) DNA test in the further clinical management of women with atypical squamous cells of undetermined significance (ASC-US). Methods 197 women diagnosed as ASC-US by liquid-based thinprep cytology test (TCT) underwent the hr-HPV DNA test (the hybrid capture 2, HCⅡ) and colposcopic-directed cervical biopsy respectively. Analyzed difference of squamous intraepithelial lesion (SIL) and squamous cell carcinoma (SCC) between the hr-HPV positive group and the hr-HPV negative group. Assessed predictive value of screening cervical SIL or SCC by the hr-HPV DNA test. Results The ratio of SIL and SCC in the hr-HPV positive group was 50%and obviously higher than that of hr-HPV negative group (P<0.05). In detecting SIL and SCC by hr-HPV DNA test, the sensitivity, specificity, positive predictive value and negative predictive value were 86.4%, 75.2%, 50.0%, 95.1%. Con-clusion The hr-HPV test plays an important role in triaging ASC-US. Colposcopic-directed biopsy is the next step to evaluate cervix with positive hr-HPV test. Repeating TCT is adopted for cervix with negative hr-HPV test.